Agios Pharmaceuticals Inc
AGIO
NASDAQ
Biotechnology
$33.56
USD
+0.09 (+0.27%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.00B
Volume 1.1M
Revenue
$98.34M
TTM
+140.6%
YoY
Gross Margin
92%
TTM
+4.3%
YoY
Net Income
$-411.29M
TTM
-163.3%
YoY
Operating Cash Flow
$-360.60M
TTM
+11.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 12.5 | 12.9 | 20.0 | 20.7 | 44.7 |
YoY Growth | +44.6% | +43.7% | +86.1% | +137.7% | +259.3% |
Cost of Revenue | 1.7 | 1.7 | 1.9 | 1.3 | 3.0 |
Gross Profit | 10.8 | 11.2 | 18.1 | 19.4 | 41.7 |
Selling, General & Administrative | 45.9 | 41.3 | 51.6 | 48.3 | 51.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 137.8 | 128.1 | 139.7 | 129.5 | 152.3 |
Operating Income | -127.1 | -116.9 | -121.6 | -110.0 | -110.6 |
EBITDA | -125.8 | -115.5 | -120.3 | -108.7 | -109.2 |
Other Income / Expense | 0.5 | 0.1 | 0.1 | 0.1 | 0.1 |
Total Other Income / Expense | 15.0 | 13.4 | 12.5 | 10.9 | 9.8 |
Income Before Income Taxes | -112.0 | -103.4 | -109.1 | -99.1 | -100.7 |
Income Taxes | 0.0 | 0.0 | -1.0 | 0.0 | 0.0 |
Net Income | -112.0 | -103.4 | -108.0 | -99.1 | -100.7 |
Consolidated Net Income / Loss | -112.0 | -103.4 | -108.0 | -99.1 | -100.7 |
Net Income Attributable to Common Shareholders | -112.0 | -103.4 | -108.0 | -99.1 | -100.7 |
Basic EPS | -$1.93 | -$1.78 | -$1.85 | -$1.69 | -$1.69 |
Diluted EPS | -$1.93 | -$1.78 | -$1.85 | -$1.69 | -$1.69 |
Basic Shares Outstanding | 57.9M | 58.1M | 58.4M | 58.8M | 59.5M |
Diluted Shares Outstanding | 57.9M | 58.1M | 58.4M | 58.8M | 59.5M |